추천 제품
일반 설명
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
애플리케이션
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
결합
View this factors role in the Coagulation Cascade
단위 정의
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
물리적 형태
Aqueous solution containing 50% (v/v) glycerol
면책조항
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease.
Alkim H., et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2011)
Double trouble: Duchenne muscular dystrophy and hemophilia.
Muge Gokce et al.
Pediatric blood & cancer, 60(3), 525-525 (2012-12-21)
Sweta Gupta et al.
British journal of haematology, 161(3), 424-433 (2013-02-26)
This study prospectively compared the effect of secondary prophylaxis to episodic treatment on target joint (TJ) range of motion (ROM), number of joint haemorrhages and new TJ development in patients with moderate or severe haemophilia. Two-hundred and eighty-six males, 17%
History of prophylaxis.
E Berntorp
Haemophilia : the official journal of the World Federation of Hemophilia, 19(2), 163-165 (2013-02-20)
Keiichiro Kume et al.
Internal medicine (Tokyo, Japan), 46(17), 1323-1329 (2007-09-11)
Recent investigations suggest that activation of coagulation and fibrinolysis occurs in patients with ulcerative colitis (UC). However, the role of the hypercoagulable state in UC has not been determined. On the other hand, there are no reports dealing with coagulation
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.